Post-COVID-19-associated morbidity in children, adolescents, and adults: A matched cohort study including more than 157,000 individuals with COVID-19 in Germany

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Martin Roessler - , Zentrum für evidenzbasierte Gesundheitsversorgung, Zentrum für Evidenzbasierte Gesundheitsversorgung, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)
  • Falko Tesch - , Zentrum für evidenzbasierte Gesundheitsversorgung, Zentrum für Evidenzbasierte Gesundheitsversorgung, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)
  • Manuel Batram - , Universität Bielefeld (Autor:in)
  • Josephine Jacob - , Charité – Universitätsmedizin Berlin (Autor:in)
  • Friedrich Loser - , Techniker Krankenkasse (Autor:in)
  • Oliver Weidinger - , AOK Bayern (Autor:in)
  • Danny Wende - , Professur für Quantitative Verfahren, insbesondere Ökonometrie, BARMER Institut für Gesundheitssystemforschung (bifg), Freie Universität (FU) Berlin (Autor:in)
  • Annika Vivirito - , Charité – Universitätsmedizin Berlin (Autor:in)
  • Nicole Toepfner - , Klinik und Poliklinik für Kinder- und Jugendmedizin, Medizinische Universität Innsbruck, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)
  • Franz Ehm - , Zentrum für evidenzbasierte Gesundheitsversorgung, Professur für Betriebswirtschaftslehre, insbesondere Industrielles Management (IM), Zentrum für Evidenzbasierte Gesundheitsversorgung, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)
  • Martin Seifert - , Zentrum für evidenzbasierte Gesundheitsversorgung, Zentrum für Evidenzbasierte Gesundheitsversorgung, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)
  • Oliver Nagel - , Charité – Universitätsmedizin Berlin (Autor:in)
  • Christina König - , Techniker Krankenkasse (Autor:in)
  • Roland Jucknewitz - , AOK Bayern (Autor:in)
  • Jakob Peter Armann - , Klinik und Poliklinik für Kinder- und Jugendmedizin, Medizinische Universität Innsbruck, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)
  • Reinhard Berner - , Klinik und Poliklinik für Kinder- und Jugendmedizin, Medizinische Universität Innsbruck, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)
  • Marina Treskova-Schwarzbach - , Robert Koch-Institut (Autor:in)
  • Dagmar Hertle - , BARMER Institut für Gesundheitssystemforschung (bifg) (Autor:in)
  • Stefan Scholz - , Robert Koch-Institut (Autor:in)
  • Stefan Stern - , AOK Bayern (Autor:in)
  • Pedro Ballesteros - , BARMER Institut für Gesundheitssystemforschung (bifg) (Autor:in)
  • Stefan Baßler - , AOK PLUS (Autor:in)
  • Barbara Bertele - , Techniker Krankenkasse (Autor:in)
  • Uwe Repschläger - , BARMER Institut für Gesundheitssystemforschung (bifg) (Autor:in)
  • Nico Richter - , DAK-Gesundheit (Autor:in)
  • Cordula Riederer - , DAK-Gesundheit (Autor:in)
  • Franziska Sobik - , DAK-Gesundheit (Autor:in)
  • Anja Schramm - , Zentrum für evidenzbasierte Gesundheitsversorgung, AOK Bayern, Universitätsklinikum Regensburg (Autor:in)
  • Claudia Schulte - , BARMER Institut für Gesundheitssystemforschung (bifg) (Autor:in)
  • Lothar Wieler - , Robert Koch-Institut (Autor:in)
  • Jochen Walker - , Charité – Universitätsmedizin Berlin (Autor:in)
  • Christa Scheidt-Nave - , Robert Koch-Institut (Autor:in)
  • Jochen Schmitt - , Zentrum für evidenzbasierte Gesundheitsversorgung, Zentrum für Evidenzbasierte Gesundheitsversorgung, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)

Abstract

BACKGROUND: Long-term health sequelae of the Coronavirus Disease 2019 (COVID-19) are a major public health concern. However, evidence on post-acute COVID-19 syndrome (post-COVID-19) is still limited, particularly for children and adolescents. Utilizing comprehensive healthcare data on approximately 46% of the German population, we investigated post-COVID-19-associated morbidity in children/adolescents and adults.

METHODS AND FINDINGS: We used routine data from German statutory health insurance organizations covering the period between January 1, 2019 and December 31, 2020. The base population included all individuals insured for at least 1 day in 2020. Based on documented diagnoses, we identified individuals with polymerase chain reaction (PCR)-confirmed COVID-19 through June 30, 2020. A control cohort was assigned using 1:5 exact matching on age and sex, and propensity score matching on preexisting medical conditions. The date of COVID-19 diagnosis was used as index date for both cohorts, which were followed for incident morbidity outcomes documented in the second quarter after index date or later.Overall, 96 prespecified outcomes were aggregated into 13 diagnosis/symptom complexes and 3 domains (physical health, mental health, and physical/mental overlap domain). We used Poisson regression to estimate incidence rate ratios (IRRs) with 95% confidence intervals (95% CIs). The study population included 11,950 children/adolescents (48.1% female, 67.2% aged between 0 and 11 years) and 145,184 adults (60.2% female, 51.1% aged between 18 and 49 years). The mean follow-up time was 236 days (standard deviation (SD) = 44 days, range = 121 to 339 days) in children/adolescents and 254 days (SD = 36 days, range = 93 to 340 days) in adults. COVID-19 and control cohort were well balanced regarding covariates. The specific outcomes with the highest IRR and an incidence rate (IR) of at least 1/100 person-years in the COVID-19 cohort in children and adolescents were malaise/fatigue/exhaustion (IRR: 2.28, 95% CI: 1.71 to 3.06, p < 0.01, IR COVID-19: 12.58, IR Control: 5.51), cough (IRR: 1.74, 95% CI: 1.48 to 2.04, p < 0.01, IR COVID-19: 36.56, IR Control: 21.06), and throat/chest pain (IRR: 1.72, 95% CI: 1.39 to 2.12, p < 0.01, IR COVID-19: 20.01, IR Control: 11.66). In adults, these included disturbances of smell and taste (IRR: 6.69, 95% CI: 5.88 to 7.60, p < 0.01, IR COVID-19: 12.42, IR Control: 1.86), fever (IRR: 3.33, 95% CI: 3.01 to 3.68, p < 0.01, IR COVID-19: 11.53, IR Control: 3.46), and dyspnea (IRR: 2.88, 95% CI: 2.74 to 3.02, p < 0.01, IR COVID-19: 43.91, IR Control: 15.27). For all health outcomes combined, IRs per 1,000 person-years in the COVID-19 cohort were significantly higher than those in the control cohort in both children/adolescents (IRR: 1.30, 95% CI: 1.25 to 1.35, p < 0.01, IR COVID-19: 436.91, IR Control: 335.98) and adults (IRR: 1.33, 95% CI: 1.31 to 1.34, p < 0.01, IR COVID-19: 615.82, IR Control: 464.15). The relative magnitude of increased documented morbidity was similar for the physical, mental, and physical/mental overlap domain. In the COVID-19 cohort, IRs were significantly higher in all 13 diagnosis/symptom complexes in adults and in 10 diagnosis/symptom complexes in children/adolescents. IRR estimates were similar for age groups 0 to 11 and 12 to 17. IRs in children/adolescents were consistently lower than those in adults. Limitations of our study include potentially unmeasured confounding and detection bias.

CONCLUSIONS: In this retrospective matched cohort study, we observed significant new onset morbidity in children, adolescents, and adults across 13 prespecified diagnosis/symptom complexes, following COVID-19 infection. These findings expand the existing available evidence on post-COVID-19 conditions in younger age groups and confirm previous findings in adults.

TRIAL REGISTRATION: ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT05074953.

Details

OriginalspracheEnglisch
Seiten (von - bis)e1004122
FachzeitschriftPLoS medicine
Jahrgang19
Ausgabenummer11
PublikationsstatusVeröffentlicht - Nov. 2022
Peer-Review-StatusJa

Externe IDs

PubMedCentral PMC9648706
Scopus 85141893114

Schlagworte

Ziele für nachhaltige Entwicklung

Schlagwörter

  • Adolescent, Adult, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Cohort Studies, COVID-19/epidemiology, COVID-19 Testing, Germany/epidemiology, Morbidity, Retrospective Studies, Young Adult, Middle Aged, Post-Acute COVID-19 Syndrome